Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,280 | 200 | 99.6% |
| Education | $12.07 | 4 | 0.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $1,090 | 42 | $0 (2018) |
| ABBVIE INC. | $685.20 | 40 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $350.36 | 44 | $0 (2020) |
| GlaxoSmithKline, LLC. | $300.49 | 19 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $176.82 | 6 | $0 (2024) |
| Allergan Inc. | $141.83 | 13 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $106.32 | 13 | $0 (2017) |
| Lilly USA, LLC | $106.29 | 7 | $0 (2021) |
| PFIZER INC. | $72.27 | 6 | $0 (2021) |
| Axsome Therapeutics, Inc. | $45.62 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $565.49 | 29 | ABBVIE INC. ($465.39) |
| 2023 | $123.58 | 6 | GlaxoSmithKline, LLC. ($97.38) |
| 2022 | $256.07 | 17 | GlaxoSmithKline, LLC. ($116.59) |
| 2021 | $269.37 | 20 | AbbVie Inc. ($125.44) |
| 2020 | $108.40 | 7 | Lilly USA, LLC ($63.90) |
| 2019 | $201.12 | 28 | Allergan Inc. ($128.80) |
| 2018 | $728.69 | 40 | Daiichi Sankyo Inc. ($601.49) |
| 2017 | $1,039 | 57 | Daiichi Sankyo Inc. ($488.25) |
All Payment Transactions
204 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/10/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $8.74 | General |
| Category: NEUROSCIENCE | ||||||
| 10/05/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.82 | General |
| Category: NEUROSCIENCE | ||||||
| 10/04/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $11.26 | General |
| Category: NEUROSCIENCE | ||||||
| 09/11/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $7.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/23/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $27.45 | General |
| Category: NEUROSCIENCE | ||||||
| 08/18/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.14 | General |
| Category: NEUROSCIENCE | ||||||
| 08/07/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/24/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $26.91 | General |
| Category: NEUROSCIENCE | ||||||
| 07/22/2024 | Axsome Therapeutics, Inc. | Auvelity (Drug) | Food and Beverage | In-kind items and services | $26.34 | General |
| Category: Psychology/Psychiatric | ||||||
| 07/12/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.97 | General |
| Category: NEUROSCIENCE | ||||||
| 07/02/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 06/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.56 | General |
| Category: NEUROSCIENCE | ||||||
| 06/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $10.10 | General |
| Category: NEUROSCIENCE | ||||||
| 06/18/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $12.16 | General |
| Category: NEUROSCIENCE | ||||||
| 06/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $7.93 | General |
| Category: NEUROSCIENCE | ||||||
| 05/21/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $31.52 | General |
| Category: NEUROSCIENCE | ||||||
| 05/13/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $32.22 | General |
| Category: NEUROSCIENCE | ||||||
| 05/09/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.54 | General |
| Category: NEUROSCIENCE | ||||||
| 05/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.70 | General |
| Category: NEUROSCIENCE | ||||||
| 04/23/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Respiratory | ||||||
| 03/27/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: NEUROSCIENCE | ||||||
| 03/08/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.69 | General |
| Category: NEUROSCIENCE | ||||||
| 02/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $8.98 | General |
| Category: NEUROSCIENCE | ||||||
| 02/10/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $12.50 | General |
| Category: NEUROSCIENCE | ||||||
| 02/02/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $33.20 | General |
| Category: NEUROSCIENCE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 886 | 2,261 | $381,229 | $159,498 |
| 2022 | 26 | 990 | 2,267 | $392,247 | $169,121 |
| 2021 | 22 | 922 | 1,796 | $279,333 | $132,370 |
| 2020 | 20 | 800 | 1,226 | $190,039 | $88,685 |
All Medicare Procedures & Services
96 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 68 | 210 | $84,000 | $48,675 | 57.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 108 | 393 | $105,714 | $30,405 | 28.8% |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 42 | 126 | $44,100 | $23,226 | 52.7% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 43 | 123 | $33,250 | $18,399 | 55.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 106 | $20,667 | $6,489 | 31.4% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 27 | 77 | $12,320 | $4,628 | 37.6% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 21 | 141 | $8,460 | $4,481 | 53.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 21 | 141 | $11,280 | $4,279 | 37.9% |
| 99487 | Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 25 | 46 | $5,980 | $3,918 | 65.5% |
| 80305 | Testing for presence of drug, read by direct observation | Office | 2023 | 56 | 288 | $15,810 | $3,511 | 22.2% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 14 | 15 | $9,000 | $1,696 | 18.8% |
| 99406 | Smoking and tobacco use intensive counseling, 4-10 minutes | Office | 2023 | 36 | 110 | $3,798 | $1,494 | 39.3% |
| 99491 | Chronic care management services for two or more chronic conditions, first 30 minutes provided personally by health care professional, per calendar month | Office | 2023 | 21 | 23 | $2,760 | $1,157 | 41.9% |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | Office | 2023 | 16 | 38 | $4,513 | $814.24 | 18.0% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 11 | 11 | $2,860 | $776.30 | 27.1% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 37 | 46 | $1,518 | $757.16 | 49.9% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 20 | 20 | $2,665 | $660.60 | 24.8% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 21 | 30 | $1,650 | $587.42 | 35.6% |
| 82306 | Vitamin d-3 level | Office | 2023 | 20 | 21 | $1,260 | $580.20 | 46.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 43 | 53 | $1,325 | $548.55 | 41.4% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 32 | 37 | $1,480 | $459.20 | 31.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 40 | 52 | $1,820 | $395.72 | 21.7% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 31 | 42 | $1,092 | $380.80 | 34.9% |
| 84439 | Thyroxine (thyroid chemical), free | Office | 2023 | 34 | 42 | $840.00 | $353.60 | 42.1% |
| 94010 | Test to measure expiratory airflow and volume | Office | 2023 | 16 | 17 | $1,105 | $297.60 | 26.9% |
About Dr. David Diffine, MD
Dr. David Diffine, MD is a Family Medicine healthcare provider based in Blytheville, Arkansas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/24/2005. The National Provider Identifier (NPI) number assigned to this provider is 1679576631.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Diffine, MD has received a total of $3,292 in payments from pharmaceutical and medical device companies, with $565.49 received in 2024. These payments were reported across 204 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($3,280).
As a Medicare-enrolled provider, Diffine has provided services to 3,598 Medicare beneficiaries, totaling 7,550 services with total Medicare billing of $549,673. Data is available for 4 years (2020–2023), covering 96 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Other Specialties Family Medicine
- Location Blytheville, AR
- Active Since 05/24/2005
- Last Updated 02/07/2024
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1679576631
Products in Payments
- VRAYLAR (Drug) $739.77
- Morphabond ER (Drug) $607.15
- Movantik (Drug) $365.93
- TRELEGY ELLIPTA (Drug) $229.99
- LATUDA (Drug) $191.65
- UTIBRON (Drug) $154.71
- INJECTAFER (Drug) $116.66
- EMGALITY (Drug) $106.29
- MOVANTIK (Drug) $98.28
- ANORO (Drug) $70.50
- BELSOMRA (Drug) $54.57
- FARXIGA (Drug) $47.37
- LYRICA (Drug) $47.30
- JANUVIA (Drug) $47.03
- Auvelity (Drug) $45.62
- UBRELVY (Drug) $39.90
- Axonics r-SNM System (Device) $36.44
- REXULTI (Drug) $32.94
- XIFAXAN (Drug) $32.10
- JARDIANCE (Drug) $24.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Blytheville
Chimere Ashley Hammett, M.d, M.D
Family Medicine — Payments: $1,960
Valencia Andrews-Pirtle, Md, MD
Family Medicine — Payments: $499.25
Ronald Smith, Md, MD
Family Medicine — Payments: $479.78
Ashley Gross
Family Medicine — Payments: $12.44